Baseimmune, an early-stage UK biotech startup, is combining big data and biological expertise to predict how viruses will change and identify ‘future-proof’ antigens that will form the crucial elements of the next generation of vaccines.
In order to further the development of its platform and start pre-clinical development in the lab, Baseimmune has secured a GBP685,000 investment, led by European university VC fund, Creator Fund, and includes Mike Watson, ex-president of Moderna’s infectious disease spin-out with the support of Vaccitech and Oxford University. Maki VC and Rockmount Seed Investments also joined the round.
The team has also initiated the preclinical development of a number of its own vaccine candidates including a universal Covid vaccine and a veterinary vaccine against African Swine Fever Virus (ASFV).
Baseimmune’s software generates vaccine antigens associated with agricultural and human diseases, such as Malaria and Covid.
Read more at Private Equity Wire
Image Source
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.